53,744 Bristol Myers Squibb Company $BMY Shares Sold by Douglas Lane & Associates LLC

Douglas Lane & Associates LLC lessened its stake in Bristol Myers Squibb Company (NYSE:BMY) by 3.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,502,440 shares of the biopharmaceutical company’s stock after selling 53,744 shares during the quarter. Bristol Myers Squibb accounts for approximately 1.1% of Douglas Lane & Associates LLC’s holdings, making the stock its 22nd biggest position. Douglas Lane & Associates LLC owned approximately 0.07% of Bristol Myers Squibb worth $93,752,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Davis Asset Management L.P. bought a new stake in shares of Bristol Myers Squibb during the 2nd quarter valued at $27,000. Addison Advisors LLC purchased a new position in Bristol Myers Squibb during the 2nd quarter valued at $32,000. Bayban bought a new stake in Bristol Myers Squibb during the 4th quarter valued at $31,000. Groupe la Francaise raised its position in shares of Bristol Myers Squibb by 562.9% in the 2nd quarter. Groupe la Francaise now owns 590 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 501 shares in the last quarter. Finally, Kilter Group LLC purchased a new position in Bristol Myers Squibb in the second quarter worth $35,000. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Performance

Shares of NYSE BMY traded down $0.04 during trading on Friday, reaching $59.53. The stock had a trading volume of 3,518,427 shares, compared to its average volume of 11,971,028. The stock has a market cap of $121.61 billion, a PE ratio of 13.11, a P/E/G ratio of 0.28 and a beta of 0.19. The firm’s 50 day moving average price is $64.27 and its two-hundred day moving average price is $60.28. The company has a debt-to-equity ratio of 1.89, a quick ratio of 1.38 and a current ratio of 1.53. Bristol Myers Squibb Company has a one year low of $42.52 and a one year high of $68.64.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The business had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. During the same quarter in the prior year, the company posted $1.46 earnings per share. The company’s quarterly revenue was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, research analysts forecast that Bristol Myers Squibb Company will post 6.95 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd will be paid a $0.63 dividend. The ex-dividend date is Friday, October 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.2%. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 55.51%.

Insider Buying and Selling at Bristol Myers Squibb

In other news, SVP Phil M. Holzer sold 500 shares of the company’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the sale, the senior vice president directly owned 16,862 shares in the company, valued at approximately $1,138,185. This represents a 2.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 0.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on BMY. Weiss Ratings upgraded shares of Bristol Myers Squibb from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, August 18th. Leerink Partners downgraded Bristol Myers Squibb from an “outperform” rating to a “market perform” rating and dropped their target price for the company from $73.00 to $59.00 in a research report on Monday. BMO Capital Markets reaffirmed a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, July 27th. Roth Capital began coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They issued a “buy” rating and a $75.00 price objective for the company. Finally, TD Cowen began coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They set a “buy” rating for the company. Two research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $66.72.

Key Stories Impacting Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers reported a Phase 3 success for ZENBEXUS (iberdomide) combined with daratumumab and dexamethasone in relapsed or refractory multiple myeloma. The treatment delivered superior progression-free survival versus standard care and reduced the risk of disease progression or death by 51%, strengthening the company’s oncology pipeline and potential future growth. Bristol Myers Squibb Announces ZENBEXUS Phase 3 Results
• Positive Sentiment: Analysts and commentators highlighted growth from newer products, including Reblozyl, which is helping offset declines in legacy medicines. A label expansion for Camzyos could provide an additional commercial opportunity. Reblozyl Growth Outlook
• Positive Sentiment: J.P. Morgan initiated or reiterated a Buy rating on BMY, adding support to the bullish case that the company’s valuation, dividend yield and pipeline offer attractive long-term risk-reward. J.P. Morgan Buy Rating
• Neutral Sentiment: Expectations for another earnings beat are supporting sentiment, with analysts pointing to BMY’s history of exceeding estimates. However, these are forecasts rather than new company results. Bristol Myers Earnings Outlook
• Neutral Sentiment: Scotiabank maintained a Hold rating, reflecting a more balanced view of BMY’s pipeline opportunities against patent, competition and execution risks. Scotiabank Hold Rating
• Negative Sentiment: Morgan Stanley issued a Sell rating, while Cantor Fitzgerald cut its price target from $59 to $53 and assigned a Neutral rating. The actions underscore concerns about valuation, competitive pressure and the eventual impact of declining older-product sales. Morgan Stanley Sell Rating

Bristol Myers Squibb Company Profile

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its research and commercial activities focus primarily on oncology, hematology, immunology, cardiovascular disease and neuroscience. The company serves patients and healthcare providers in the United States and international markets.

Bristol Myers Squibb’s portfolio includes medicines such as Opdivo and Yervoy for certain cancers, Eliquis for the prevention of blood clots and stroke, Revlimid and Pomalyst for blood cancers, and Abraxane for certain solid tumors.